About Trillium Therapeutics (TSE:TR)
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-259.65%
Return on Assets-55.25%
Trillium Therapeutics (TSE:TR) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (TSE:TR) issued its earnings results on Friday, May, 11th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.15. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 59)
- Henry Friesen M.D., Independent Director (Age 79)
Has Trillium Therapeutics been receiving favorable news coverage?
Media coverage about TR stock has been trending somewhat positive on Monday, according to Accern. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Trillium Therapeutics earned a news sentiment score of 0.13 on Accern's scale. They also gave headlines about the company an impact score of 41.45 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Trillium Therapeutics?
Shares of TR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TR stock can currently be purchased for approximately C$30.20.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$136.73 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TR)MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TR will underperform the S&P 500 over the long term. You may vote once every thirty days.